MN Services Vermogensbeheer’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18.9M | Sell |
30,313
-10,900
| -26% | -$7.42M | 0.14% | 149 |
|
|
2026
Q1 | $31.8M | Hold |
41,213
| – | – | 0.21% | 100 |
|
|
2025
Q4 | $31.8M | Buy |
41,213
+713
| +2% | +$484K | 0.2% | 108 |
|
|
2025
Q3 | $22.8M | Buy |
40,500
+500
| +1% | +$283K | 0.15% | 140 |
|
|
2025
Q2 | $21M | Buy |
40,000
+400
| +1% | +$223K | 0.15% | 146 |
|
|
2025
Q1 | $25.1M | Sell |
39,600
-2,900
| -7% | -$1.99M | 0.19% | 115 |
|
|
2024
Q4 | $30.3M | Buy |
42,500
+1,200
| +3% | +$1.01M | 0.2% | 101 |
|
|
2024
Q3 | $43.4M | Sell |
41,300
-1,000
| -2% | -$1.11M | 0.3% | 67 |
|
|
2024
Q2 | $44.5M | Sell |
42,300
-1,000
| -2% | -$969K | 0.32% | 66 |
|
|
2024
Q1 | $41.7M | Sell |
43,300
-7,400
| -15% | -$7.04M | 0.3% | 72 |
|
|
2023
Q4 | $44.5M | Sell |
50,700
-1,800
| -3% | -$1.48M | 0.4% | 68 |
|
|
2023
Q3 | $43.2M | Buy |
52,500
+1,300
| +3% | +$1.02M | 0.42% | 67 |
|
|
2023
Q2 | $36.8M | Sell |
51,200
-2,000
| -4% | -$1.54M | 0.34% | 77 |
|
|
2023
Q1 | $43.7M | Buy |
53,200
+1,900
| +4% | +$1.43M | 0.45% | 57 |
|
|
2022
Q4 | $37M | Sell |
51,300
-8,200
| -14% | -$6.05M | 0.41% | 61 |
|
|
2022
Q3 | $41M | Sell |
59,500
-3,200
| -5% | -$2.01M | 0.43% | 58 |
|
|
2022
Q2 | $37.1M | Sell |
62,700
-12,700
| -17% | -$8.26M | 0.35% | 77 |
|
|
2022
Q1 | $52.7M | Sell |
75,400
-4,700
| -6% | -$2.97M | 0.35% | 75 |
|
|
2021
Q4 | $50.6M | Buy |
80,100
+1,700
| +2% | +$1.05M | 0.3% | 87 |
|
|
2021
Q3 | $47.4M | Buy |
78,400
+1,200
| +2% | +$745K | 0.29% | 90 |
|
|
2021
Q2 | $36.4M | Buy |
+77,200
| New | +$39.1M | 0.28% | 96 |
|
|
2020
Q4 | $36.8M | Buy |
76,100
+1,300
| +2% | +$702K | 0.26% | 101 |
|
|
2020
Q3 | $41.9M | Buy |
74,800
+1,100
| +1% | +$667K | 0.33% | 90 |
|
|
2020
Q2 | $46M | Buy |
+73,700
| New | +$41.8M | 0.39% | 74 |
|
|
2019
Q3 | – | Sell |
-13,672
| Closed | -$4.28M | – | 552 |
|
|
2019
Q2 | $4.28M | Hold |
13,672
| – | – | 0.05% | 380 |
|
|
2019
Q1 | $5.61M | Buy |
13,672
+200
| +1% | +$82.4K | 0.06% | 314 |
|
|
2018
Q4 | $4.4M | Buy |
13,472
+700
| +5% | +$256K | 0.07% | 313 |
|
|
2018
Q3 | $5.16M | Buy |
12,772
+300
| +2% | +$114K | 0.12% | 187 |
|
|
2018
Q2 | $4.3M | Hold |
12,472
| – | – | 0.11% | 208 |
|
|
2018
Q1 | $4.29M | Buy |
12,472
+300
| +2% | +$104K | 0.11% | 205 |
|
|
2017
Q4 | $3.81M | Sell |
12,172
-700
| -5% | -$284K | 0.12% | 192 |
|
|
2017
Q3 | $5.75M | Sell |
12,872
-200
| -2% | -$95.2K | 0.15% | 154 |
|
|
2017
Q2 | $6.42M | Buy |
13,072
+11,001
| +531% | +$4.81M | 0.18% | 131 |
|
|
2017
Q1 | $750K | Sell |
2,071
-28
| -1% | -$10.4K | 0.15% | 157 |
|
|
2016
Q4 | $731K | Buy |
2,099
+116
| +6% | +$44.1K | 0.15% | 156 |
|
|
2016
Q3 | $797K | Buy |
1,983
+34
| +2% | +$13.6K | 0.16% | 145 |
|
|
2016
Q2 | $613K | Buy |
1,949
+34
| +2% | +$13.1K | 0.14% | 162 |
|
|
2016
Q1 | $606K | Buy |
+1,915
| New | +$789K | 0.14% | 162 |
|
Other funds holding REGN
MN Services Vermogensbeheer's REGN Position: Q2 2026 in Review
MN Services Vermogensbeheer reduced its Regeneron Pharmaceuticals (REGN) stake by 26% in Q2 2026, selling an estimated $7.42M and leaving 30,313 shares worth $18.9M. The position accounts for 0.14% of the portfolio, ranked #149.
MN Services Vermogensbeheer first reported a position in REGN in Q1 2016 and has held it in 38 quarters since. The position peaked at $52.7M in Q1 2022. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- MN Services Vermogensbeheer held 30,313 shares of Regeneron Pharmaceuticals worth $18.9M as of Q2 2026.
- MN Services Vermogensbeheer sold 10,900 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $7.42M.
- Regeneron Pharmaceuticals made up 0.14% of MN Services Vermogensbeheer's portfolio in Q2 2026, its #149 holding.
- MN Services Vermogensbeheer first reported a position in Regeneron Pharmaceuticals in Q1 2016 and has held it in 38 quarters since.
- MN Services Vermogensbeheer's Regeneron Pharmaceuticals position peaked at $52.7M in Q1 2022.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on MN Services Vermogensbeheer's 13F filing for Q2 2026, filed 31 Jul 2026.